• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非典型脑膜瘤的生存预测因素

Predictors of Survival in Atypical Meningiomas.

作者信息

Da Broi Michele, Borrelli Paola, Meling Torstein R

机构信息

Faculty of Medicine, University of Oslo, 0372 Oslo, Norway.

Department of Neurosurgery, Oslo University Hospital, 0372 Oslo, Norway.

出版信息

Cancers (Basel). 2021 Apr 21;13(8):1970. doi: 10.3390/cancers13081970.

DOI:10.3390/cancers13081970
PMID:33919475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8074901/
Abstract

INTRODUCTION

Predictors of survival and progression of disease in atypical meningiomas are less well documented in the literature compared to benign meningiomas. Higher grade meningiomas tend to recur often and one of the most critical aspects is how to best deal with relapses.

METHODS

A total of 77 consecutive patients who underwent craniotomy for atypical meningioma between 1990-2010 at Oslo University Hospital (OUH) were reviewed.

RESULTS

Median age at surgery was 62.21 [interquartile range (IQR): 22.87] years. Fifty-one patients (66.2%) had neurological deficits at presentation. Fifty-four patients (70.1%) underwent gross total resection (GTR). Thirty-nine patients (50.7%) had improved/stable neurological outcomes at 6-12 months. Twenty-two patients (28.6%) underwent retreatment, of whom 20 (26.0%) were subjected to resection followed by adjuvant radiotherapy. Overall survival (OS) was significantly longer in patients <65 years ( < 0.001), with preoperative Karnofsky performance scale (KPS) score of ≥ 70 ( = 0.006), and who required no retreatment ( = 0.033). GTR significantly prolonged the retreatment-free survival rate ( < 0.001). STR carried almost a six-fold greater risk of neurological outcome deterioration ( = 0.044).

CONCLUSIONS

GTR significantly prolonged retreatment-free survival but had no significant impact on OS. STR was a significant risk factor for deteriorated neurological outcome. Age, preoperative KPS, and retreatment were all strong predictors of OS. Median time-to-retreatment (TTR) did not shorten significantly throughout repeated surgeries.

摘要

引言

与良性脑膜瘤相比,非典型脑膜瘤疾病生存和进展的预测因素在文献中的记载较少。高级别脑膜瘤往往容易复发,最关键的问题之一是如何最好地应对复发情况。

方法

回顾了1990年至2010年间在奥斯陆大学医院(OUH)接受开颅手术治疗非典型脑膜瘤的77例连续患者。

结果

手术时的中位年龄为62.21岁[四分位间距(IQR):22.87]。51例患者(66.2%)在就诊时存在神经功能缺损。54例患者(70.1%)接受了全切除(GTR)。39例患者(50.7%)在6至12个月时神经功能结局改善/稳定。22例患者(28.6%)接受了再次治疗,其中20例(26.0%)接受了切除并辅助放疗。年龄<65岁(<0.001)、术前卡诺夫斯基表现评分(KPS)≥70分(=

0.006)且无需再次治疗的患者(= 0.033)总体生存期(OS)明显更长。GTR显著延长了无再次治疗生存期(<0.001)。次全切除(STR)使神经功能结局恶化的风险几乎增加了六倍(= 0.044)。

结论

GTR显著延长了无再次治疗生存期,但对OS无显著影响。STR是神经功能结局恶化的重要危险因素。年龄、术前KPS和再次治疗均是OS的有力预测因素。在整个重复手术过程中,中位再次治疗时间(TTR)没有显著缩短。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/26d64a9d904b/cancers-13-01970-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/6324a951e18f/cancers-13-01970-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/69da258ec812/cancers-13-01970-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/9d1f86dde6d1/cancers-13-01970-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/0a6231302101/cancers-13-01970-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/26d64a9d904b/cancers-13-01970-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/6324a951e18f/cancers-13-01970-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/69da258ec812/cancers-13-01970-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/9d1f86dde6d1/cancers-13-01970-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/0a6231302101/cancers-13-01970-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/531d/8074901/26d64a9d904b/cancers-13-01970-g005.jpg

相似文献

1
Predictors of Survival in Atypical Meningiomas.非典型脑膜瘤的生存预测因素
Cancers (Basel). 2021 Apr 21;13(8):1970. doi: 10.3390/cancers13081970.
2
Predictors of Survival in Subtotally Resected WHO Grade I Skull Base Meningiomas.世界卫生组织I级次全切除颅底脑膜瘤生存的预测因素
Cancers (Basel). 2021 Mar 22;13(6):1451. doi: 10.3390/cancers13061451.
3
Adjuvant radiotherapy for atypical meningiomas.非典型脑膜瘤的辅助放疗。
J Neurosurg. 2017 Jun;126(6):1822-1828. doi: 10.3171/2016.5.JNS152809. Epub 2016 Sep 9.
4
Early adjuvant radiotherapy in the treatment of atypical meningioma.早期辅助放疗在非典型脑膜瘤治疗中的应用
J Clin Neurosci. 2016 Jun;28:87-92. doi: 10.1016/j.jocn.2015.09.021. Epub 2016 Jan 8.
5
Local control and overall survival in atypical meningioma: a retrospective study.非典型脑膜瘤的局部控制和总生存率:一项回顾性研究。
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61. doi: 10.1016/s0360-3016(99)00349-1.
6
Gamma Knife radiosurgery for intracranial benign meningiomas: follow-up outcome in 130 patients.伽玛刀放射外科治疗颅内良性脑膜瘤:130 例患者的随访结果。
Neurosurg Focus. 2019 Jun 1;46(6):E7. doi: 10.3171/2019.3.FOCUS1956.
7
Skull base atypical meningioma: long term surgical outcome and prognostic factors.颅底非典型脑膜瘤:长期手术结果及预后因素
Clin Neurol Neurosurg. 2015 Jan;128:112-6. doi: 10.1016/j.clineuro.2014.11.009. Epub 2014 Nov 24.
8
Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.大体全切除和辅助放疗是提高非典型脑膜瘤患者生存的最显著预测因素。
Cancer. 2018 Feb 15;124(4):734-742. doi: 10.1002/cncr.31088. Epub 2017 Nov 13.
9
Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas.与非颅底脑膜瘤相比,手术切除的颅底脑膜瘤具有不同的术后复发模式。
J Neurosurg. 2016 Aug;125(2):431-40. doi: 10.3171/2015.7.JNS15546. Epub 2016 Jan 1.
10
Foramen magnum meningiomas: surgical results and risks predicting poor outcomes based on a modified classification.枕大孔脑膜瘤:基于改良分类的手术结果和不良预后预测风险。
J Neurosurg. 2017 Mar;126(3):661-676. doi: 10.3171/2016.2.JNS152873. Epub 2016 May 13.

引用本文的文献

1
Supraorbital keyhole approach (SOKHA) versus endoscopic endonasal approach (EEA) for suprasellar meningioma (SSM) resection: systematic review and meta-analysis.眶上锁孔入路(SOKHA)与鼻内镜下经鼻入路(EEA)治疗鞍上脑膜瘤(SSM)的系统评价和Meta分析
Ann Med Surg (Lond). 2025 Feb 28;87(3):1552-1560. doi: 10.1097/MS9.0000000000003071. eCollection 2025 Mar.
2
Atypical and anaplastic meningiomas in the later decades of life: A national cancer database analysis.生命后期的非典型性和间变性脑膜瘤:国家癌症数据库分析。
Acta Neurochir (Wien). 2024 Jul 5;166(1):282. doi: 10.1007/s00701-024-06157-0.
3
Surgical Management of High-Grade Meningiomas.

本文引用的文献

1
Benefits of re-do surgery for recurrent intracranial meningiomas.复发性颅内脑膜瘤再手术的益处。
Sci Rep. 2020 Jan 15;10(1):303. doi: 10.1038/s41598-019-57254-5.
2
Clinical, radiological, and histopathological predictors for long-term prognosis after surgery for atypical meningiomas.非典型脑膜瘤手术后长期预后的临床、影像学和组织病理学预测因素。
Acta Neurochir (Wien). 2019 Aug;161(8):1647-1656. doi: 10.1007/s00701-019-03956-8. Epub 2019 May 31.
3
Extent of Resection in Meningioma: Predictive Factors and Clinical Implications.
高级别脑膜瘤的外科治疗
Cancers (Basel). 2024 May 23;16(11):1978. doi: 10.3390/cancers16111978.
4
The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study.建立预测非典型脑膜瘤术后复发的临床-放射组学综合模型:一项多中心研究。
J Neurooncol. 2024 Jan;166(1):59-71. doi: 10.1007/s11060-023-04511-3. Epub 2023 Dec 26.
5
The Simpson Grading: Is It Still Valid?辛普森分级:它仍然有效吗?
Cancers (Basel). 2022 Apr 15;14(8):2007. doi: 10.3390/cancers14082007.
6
A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma.基于术前血液学和临床参数的临床预后模型可预测世界卫生组织原发性II级脑膜瘤的进展。
Front Oncol. 2021 Oct 11;11:748586. doi: 10.3389/fonc.2021.748586. eCollection 2021.
7
Establishment and Validation of an Integrated Model to Predict Postoperative Recurrence in Patients With Atypical Meningioma.建立和验证用于预测非典型脑膜瘤患者术后复发的综合模型。
Front Oncol. 2021 Oct 7;11:754937. doi: 10.3389/fonc.2021.754937. eCollection 2021.
脑膜瘤切除术范围:预测因素与临床意义。
Sci Rep. 2019 Apr 11;9(1):5944. doi: 10.1038/s41598-019-42451-z.
4
Posterior fossa meningiomas: perioperative predictors of extent of resection, overall survival and progression-free survival.后颅窝脑膜瘤:手术切除范围、总生存率和无进展生存率的围手术期预测因素。
Acta Neurochir (Wien). 2019 May;161(5):1003-1011. doi: 10.1007/s00701-019-03862-z. Epub 2019 Mar 11.
5
Predictors of early progression of surgically treated atypical meningiomas.手术治疗非典型脑膜瘤早期进展的预测因素。
Acta Neurochir (Wien). 2018 Sep;160(9):1813-1822. doi: 10.1007/s00701-018-3593-x. Epub 2018 Jun 30.
6
Meningiomas: skull base versus non-skull base.脑膜瘤:颅底与非颅底
Neurosurg Rev. 2019 Mar;42(1):163-173. doi: 10.1007/s10143-018-0976-7. Epub 2018 Apr 7.
7
Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy.预测非典型脑膜瘤手术后辅助放疗局部控制的组织病理学特征。
J Neurosurg. 2018 Apr 6;130(2):443-450. doi: 10.3171/2017.9.JNS171609.
8
Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.大体全切除和辅助放疗是提高非典型脑膜瘤患者生存的最显著预测因素。
Cancer. 2018 Feb 15;124(4):734-742. doi: 10.1002/cncr.31088. Epub 2017 Nov 13.
9
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.CBTRUS统计报告:2009 - 2013年美国原发性脑和其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75. doi: 10.1093/neuonc/now207.
10
EANO guidelines for the diagnosis and treatment of meningiomas.EANO 指南:脑膜瘤的诊断与治疗。
Lancet Oncol. 2016 Sep;17(9):e383-91. doi: 10.1016/S1470-2045(16)30321-7. Epub 2016 Aug 30.